[Correction added on 14 June 2012, after first online publication: A duplicated part of the title was removed]
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib
Article first published online: 12 MAR 2012
© 2012 Wiley Publishing Asia Pty Ltd
Asia-Pacific Journal of Clinical Oncology
Volume 8, Issue 3, pages 267–274, September 2012
How to Cite
LIAM, C.-K., RUTHRANESAN, M., LEE, C.-H., PANG, Y.-K., CHUA, K.-T. and LIM, B.-K. (2012), Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pacific Journal of Clinical Oncology, 8: 267–274. doi: 10.1111/j.1743-7563.2011.01509.x
- Issue published online: 22 AUG 2012
- Article first published online: 12 MAR 2012
- Accepted for publication 28 November 2011.
- EGFR mutation unknown;
Aims: To evaluate the response and progression-free survival (PFS) of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor (EGFR) mutation status treated with gefitinib.
Methods: A retrospective analysis of consecutive patients with EGFR mutation unknown stage III or IV lung adenocarcinoma with EGFR mutation unknown treated with gefitinib until disease progression.
Results: Of 71 patients, none had complete response while 26 (36.6%) had partial response and 26 (36.6%) had stable disease. Multivariate analysis showed the independent predictor of response to gefitinib was Eastern Cooperative Oncology Group (ECOG) performance status 1 (odds ratio [OR] 5.39, 95% confidence interval [CI 1.64–17.74]P = 0.006). The median PFS was 6.5 months and was significantly longer in female than male patients (39.0 vs 21.2 weeks; P < 0.001), never smokers vs smokers (32.3 vs 8.3 weeks, P = 0.001), and stage III versus stage IV disease (44 vs 24 weeks, P = 0.021). In a multivariate Cox proportional hazards model with age group, gender, ethnicity, smoking history, disease stage, ECOG performance status and prior cytotoxic chemotherapy as covariates, the independent predictors of longer median PFS were female gender (HR 95% CI 0.38 [0.22–0.66]; P < 0.001) and stage III disease (HR 95% CI 0.54 [0.30–0.98], P = 0.042).
Conclusion: In our patients with EGFR mutation unknown advanced lung adenocarcinoma treated with gefitinib, the response rate was 36.6% and the median PFS was significantly longer in female patients, never smokers and patients with stage III disease.